On June 9, 2022 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, reported that the company will participate in investor meetings at the JMP Securities Life Sciences Conference being held in New York City, June 15 – 16, 2022 (Press release, Hookipa Biotech, JUN 9, 2022, View Source [SID1234615805]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 9, 2022 Ferring Pharmaceuticals reported it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions (Press release, Ferring, JUN 9, 2022, View Source [SID1234615804]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Olamkicept is the first and only clinical stage selective interleukin-6 inhibitor that works through the trans-signaling mechanism. Interleukin-6 is associated with a number of inflammatory conditions, such as IBD. In 2021, positive results from a Phase 2 study evaluating the efficacy and safety of olamkicept in patients with active ulcerative colitis (UC) were presented at the European Crohn’s and Colitis Organization (ECCO) meeting.

Ferring had previously entered into a license agreement with I-Mab in 2016 that granted I-Mab exclusive rights to develop and commercialize olamkicept in Greater China and South Korea. This new collaboration enables Ferring to invest in the development of olamkicept globally and provides an option for I-Mab to collaborate with Ferring in the future development of olamkicept at a pre-defined development milestone. The financial details of this deal are undisclosed.

"Ferring is committed to developing novel therapies where unmet needs remain for patients living with complex medical conditions, including inflammatory bowel disease," said Araz Raoof, President of Ferring Research Institute and Senior Vice President, Global Drug Discovery & External Innovation at Ferring Pharmaceuticals. "We are excited to expand our collaboration and advance olamkicept globally, as we continue to invest in our specialty area of gastroenterology."

On June 9 2022 Race Oncology Limited ("Race") reported the Board has approved an on-market share buyback for up to 4 million Race Oncology ordinary shares over the next 12 months (Press release, Race Oncology, JUN 9, 2022, View Source [SID1234615803]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Race Oncology’s Board believes an on-market buyback is an efficient capital management option available to maximize shareholder value. All committed clinical and preclinical programs as outlined in the November 2021 Share Purchase Plan remain fully funded.

The structure of an on-market buyback allows Race Oncology to take advantage of share price volatility through opportunistic share purchases during periods in which the share price does not reflect the robust outlook for the company.

The on-market buyback does not require shareholder approval and will be executed at Race Oncology’s discretion. The buyback will remain in place for a period of up to 12 months or until completed. Race may vary, suspend or terminate the buyback based on its view of market conditions and other factors. The shares that are bought will be purchased at a price of not more than 5% above the 5-day volume weighted average price of Race’s shares.

On June 9, 2022 ORPHELIA Pharma and Gustave Roussy reported the publication in the scientific journal Pharmaceuticals of the work related to the development of the first temozolomide oral suspension for the treatment of young children and adults with cancer and presenting difficulties to swallow temozolomide capsules (Annereau M. et al., Pharmaceuticals, 2022) (Press release, ORPHELIA Pharma, JUN 9, 2022, View Source;utm_medium=rss&utm_campaign=orphelia-pharma-and-gustave-roussy-announce-the-publication-in-pharmaceuticals-of-the-scientific-work-related-to-the-development-of-the-first-temozolomide-oral-suspension-for-children [SID1234615800]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Since 2015, we have been manufacturing a liquid temozolomide hospital compounded formulation to address the needs of young patients treated in our hospital and a few partner centers," explains Maxime Annereau, pharmacist at Gustave Roussy and the originator of this project. "In collaboration with ORPHELIA Pharma, we carried out the necessary research work to optimize the physico-chemical properties and the stability of the suspension. Then we conducted a palatability study in order to select the aroma capable of covering the bitterness of temozolomide in the most efficient way. The development of this concentrated suspension has made it possible to obtain a form adapted to the needs of patients and caregivers", he adds.

"The work done in collaboration with our partner Gustave Roussy led to a prototype of KIMOZO, an industrialized and patented version of this drinkable and highly concentrated suspension. KIMOZO is currently in an advanced phase of clinical development," says Jeremy Bastid, Chief Development Officer of ORPHELIA Pharma. "Temozolomide is an essential drug in the management of many pediatric cancers, including relapsed or refractory neuroblastoma which unfortunately affects very young children. Thanks to the results of this collaboration, we intend to make this pediatric formulation available to patients soon," he concludes.

About KIMOZO 40 mg/ml

KIMOZO 40 mg/ml is a liquid, taste-masked and ready-to-use oral formulation of temozolomide developed in collaboration between the pharmacists and clinicians of Gustave Roussy and the development team of ORPHELIA Pharma. The formulation of KIMOZO has been covered by a patent application in Europe and in the US.

On June 9, 2022 Massive Bio, Inc., a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric clinical trial enrollment for oncology, and AdhereTech, a pioneer and leading provider of smart devices that connect patients to care with real-time interventions, reported their partnership to provide advanced, data-driven digital health technology solutions, focusing in oral oncolytic agents providing real-time integrated access to care for cancer patients to precision oncology drugs and leading-edge clinical trials (Press release, Massive Bio, JUN 9, 2022, View Source [SID1234615799]). Both companies were recognized in the 2022 NYC Digital Health 100, which showcases the most exciting digital health companies in the New York region.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Massive Bio and AdhereTech have committed to combining their products and services to offer global, comprehensive solutions to measure, analyze and monitor precision oncology medication adherence for patients participating in clinical trials and those prescribed commercially available treatments. Both companies currently are contracted with leading pharmaceutical companies and major specialty pharmacies. Their work with payers, pharmacies, and pharmaceutical companies to develop adherence programs utilizing device-generated data to optimize processes and improve cost-effective measures for specialty drug and clinical trial programs that may save the industry hundreds of billions of dollars per year.

"While the conversation around digital health and pharma has expanded well beyond adherence, in oncology it provides the link between cost-effective treatments, and an opportunity to prioritize clinical trials when most appropriate," mentioned Selin Kurnaz, CEO and Co-Founder of Massive Bio. "Even modest improvements can lead to huge cost savings for payers and the pharmaceutical research industry while allowing streamlined access in real-time to effective on-label precision oncology treatments. It is a win-win situation for all stakeholders, from patients to specialty pharmacies, payers, and the commercial and cancer research ecosystem. AdhereTech is one of the few companies successfully achieving those goals, and we are excited about this collaboration."

With over 13,000 active cancer clinical trials in the US at any given time, and dozens of biomarkers and precision oncology molecules under study, Massive Bio aims to use AI and patient-centric concierge services at scale to reach cancer patients globally and accelerate the oncology research and development infrastructure. Massive Bio had recently announced the launch of its NASA-style Oncology Clinical Trial Command Center (OCTCC) to disrupt and accelerate trial enrollment, and also the launch of its 100K Cancer Clinical Trial Singularity Program aimed at matching 100,000 cancer patients in real-time to cutting-edge clinical trials using its Massive Bio’s AI-based technology, website and apps across iOS and Android platforms, expanding their presence as a global company with country-level success in 12 markets.

AdhereTech is a leader in medication programs, providing commercialized digital solutions to measure and manage medication adherence in a variety of settings, including academics, clinical trials, and commercially prescribed treatments. It develops and produces treatment management solutions utilizing smart devices with integrated cellular technology that seamlessly connects patients in real-time to confirm when patients take their medication and provides two-way communications to ensure dosing regimens are followed and reports and escalate the reasons for and missed doses.

"The Aidia System creates personalized patient support with specialty pharmacies and healthcare teams, enabling timely health interventions when necessary, and clinical trials can benefit from those key interventions," said Chris O’Brien, Chief Executive Officer of AdhereTech. "Upon learning of Massive Bio’s traction in the oncology space and the opportunities of using our Aidia System, expansive network, and real-world data to help patients, physicians and the cancer research industry at a technology-enabled scale, it made absolute sense to explore and operationalize this partnership."

"Our AI-enabled clinical trial and precision oncology therapy-finding technology works at its best when paired up with real-time patient-reported insights" said Arturo Loaiza-Bonilla, M.D., Co-Founder of Massive Bio. "By leveraging real-time data from AdhereTech’s Smart Adherence System in combination with our SYNERGY-AI cancer trial matching platform, we can identify key opportunities for clinical trial enrollment while also optimizing medication adherence and access in both precision oncology care and cancer research."

"At AdhereTech, we strive to bring data, analytics, and new technologies to market to serve patients and life science companies with better resources in the vital clinical research and treatment realms," said Gregory Gallo, Chief Revenue Officer of AdhereTech. "We’re excited to partner with a cutting-edge solutions provider in the critical oncology therapeutic category. Integrating technology and resources will streamline patient journeys and achieve more consistent engagement, enhance care, and ultimately improve outcomes and scientific advances," added Gallo.